3.6. Safety analysis
bleeding, TEAEs, pyrexia, deaths, TEAE
ADVERSE EVENTS, EVENTS, BLEEDING, ADVERSE EVENT
All enrolled patients received 5 days of once-daily exposure to avatrombopag with no significant safety issues observed. No deaths occurred and 5 serious AEs were reported in 2 (4%) patients, with none considered related to avatrombopag treatment. The majority of patients had TEAEs that were mild (n = 3 [6%]) or moderate (n = 3 [6%]), with 1 (2%) severe TEAE of pyrexia; none led to discontinuation or were considered related to avatrombopag (Table Overview of treatment-emergent adverse events.TEAE = treatment-emergent adverse event.Two mild bleeding events were reported, with both considered unrelated to avatrombopag by the investigator. One patient, prescribed 60 mg avatrombopag, had a baseline platelet count of 36 × 10